China Universal Asset Management Co. Ltd. Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

China Universal Asset Management Co. Ltd. raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 353.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,364 shares of the company's stock after purchasing an additional 8,860 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Neurocrine Biosciences were worth $1,497,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of NBIX. Total Clarity Wealth Management Inc. purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $240,000. State of Michigan Retirement System raised its position in shares of Neurocrine Biosciences by 0.9% during the 4th quarter. State of Michigan Retirement System now owns 23,581 shares of the company's stock valued at $3,107,000 after buying an additional 200 shares in the last quarter. Clarus Wealth Advisors purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $252,000. Sendero Wealth Management LLC raised its position in shares of Neurocrine Biosciences by 1.4% during the 4th quarter. Sendero Wealth Management LLC now owns 19,817 shares of the company's stock valued at $2,611,000 after buying an additional 271 shares in the last quarter. Finally, Pacer Advisors Inc. raised its position in shares of Neurocrine Biosciences by 79.1% during the 4th quarter. Pacer Advisors Inc. now owns 14,608 shares of the company's stock valued at $1,925,000 after buying an additional 6,450 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. StockNews.com upgraded shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. Canaccord Genuity Group reiterated a "buy" rating and issued a $150.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, December 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday, December 12th. They issued a "buy" rating and a $136.00 target price on the stock. Stifel Nicolaus lifted their target price on shares of Neurocrine Biosciences from $141.00 to $144.00 and gave the stock a "buy" rating in a research report on Monday, December 18th. Finally, The Goldman Sachs Group boosted their price objective on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a "buy" rating in a research report on Thursday, January 25th. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.92.

Insider Activity

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the company's stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the completion of the sale, the insider now directly owns 35,882 shares of the company's stock, valued at $5,018,456.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 200 shares of the company's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $140.00, for a total value of $28,000.00. Following the completion of the transaction, the insider now directly owns 7,507 shares in the company, valued at $1,050,980. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Darin Lippoldt sold 10,000 shares of the company's stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the completion of the transaction, the insider now owns 35,882 shares of the company's stock, valued at $5,018,456.52. The disclosure for this sale can be found here. Insiders sold 283,011 shares of company stock valued at $38,578,868 over the last three months. Insiders own 4.40% of the company's stock.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX traded up $0.02 during mid-day trading on Thursday, hitting $137.61. 1,015,232 shares of the company's stock were exchanged, compared to its average volume of 875,450. Neurocrine Biosciences, Inc. has a one year low of $89.04 and a one year high of $148.37. The business has a fifty day moving average price of $137.14 and a 200 day moving average price of $125.35. The company has a market cap of $13.69 billion, a PE ratio of 56.86, a P/E/G ratio of 0.88 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. Neurocrine Biosciences's quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.88 earnings per share. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.88 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.